Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | CD38 | P28907 | 1/20 | 0.33 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16302272 | 0.82 | MAPK1 (0.45) | MAPK1BACE1BACE2OPRL1IRAK4 | |
| SCHEMBL879711 | 0.82 | MAPK1 (0.45) | MAPK1BACE1BACE2OPRL1IRAK4 | |
| SCHEMBL1343010 | 0.81 | MAPK1 (0.43) | MAPK1BACE1BACE2OPRL1PIM1 | |
| SCHEMBL15830060 | 0.81 | BACE1 (0.48) | MAPK1BACE1BACE2OPRL1PIM1 | |
| SCHEMBL10291039 | 0.79 | MAPK1 (0.53) | MAPK1BACE1BACE2IRAK4PIM1 | |
| SCHEMBL15830063 | 0.79 | MAPK1 (0.46) | MAPK1BACE1BACE2OPRL1IRAK4 | |
| SCHEMBL171233 | 0.78 | BACE1 (0.46) | MAPK1BACE1BACE2OPRL1PIM1 | |
| SCHEMBL15830062 | 0.76 | GAK (0.47) | MAPK1NSD2PDCD1CD274GAK | |
| SCHEMBL9847914 | 0.75 | POLB (0.38) | — | |
| SCHEMBL15830028 | 0.72 | MAPK1 (0.46) | MAPK1BACE1BACE2IRAK4PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391089-B2 | PRMT5 inhibitors and uses therof | Epizyme, Inc. (US) | 2019-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391089-B2 | PRMT5 inhibitors and uses therof | PRMT5, PRMT1, PRMT6 | MAPK1 2668/4885BACE1 1014/4885BACE2 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.